Skip to main content

Table 2 Treatment details and prognoses of first-line chemotherapy

From: Serum albumin level as a potential marker for deciding chemotherapy or best supportive care in elderly, advanced non-small cell lung cancer patients with poor performance status

 

Single-agent (N = 20)

Platinum doublet (N = 11)

Regimen

 Gemcitabine

8 (40.0%)

0

 Vinorelbine

6 (30.0%)

0

 Docetaxel

5 (25.0%)

0

 Pemetrexed

1 (5.0%)

0

 Carboplatin + weekly paclitaxel

0

9 (81.8%)

 Carboplatin + gemcitabine

0

1 (9.1%)

 Carboplatin + S-1

0

1 (9.1%)

Response rate (%)

0

45.4%

Disease control rate (%)

55.0%

54.5%

Progression free survival (month)

2.87 [0.60–7.27]

5.43 [1.58–8.07]

Number of treatment cycles

2.00 [1.00–2.25]

3.00 [1.00–4.00]

Early termination (only 1 cycle) (%)

7 (35.0%)

4 (36.4%)

Cause of cessation

 Adverse event

11 (55.0%)

4 (36.4%)

 Deterioration of physical condition

5 (25.0%)

0

 Completion of 4–6 cycles

0

5 (45.5%)

 Progressive disease

3 (15.0%)

1 (9.1%)

 Patient’s request

1 (5.0%)

1 (9.1%)

  1. Categorical data are presented as numbers (percentages) whereas continuous data are presented as medians (interquartile ranges)